

# Robert J Motzer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/921299/publications.pdf>

Version: 2024-02-01

467  
papers

85,370  
citations

967

118  
h-index

448

280  
g-index

474  
all docs

474  
docs citations

474  
times ranked

41663  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	9.4	110
2	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2022, 81, 266-271.	0.9	33
3	Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. <i>Acta Oncologica</i> , 2022, 61, 52-57.	0.8	0
4	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 71-90.	2.3	248
5	Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 292-303.	5.1	42
6	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
7	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.	0.9	22
8	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	3.4	75
9	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. <i>Journal of Clinical Oncology</i> , 2022, 40, 2333-2341.	0.8	72
10	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
11	Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. <i>European Urology Focus</i> , 2022, 8, 1278-1288.	1.6	11
12	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938.	0.8	33
13	Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 383-400.	1.1	20
14	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.	2.0	103
15	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 768-780.	5.1	23
16	Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 3248-3255.	3.2	24
17	Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2022, 20, .	0.1	0
18	Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 888-898.	5.1	114

#	ARTICLE	IF	CITATIONS
19	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2022, 12, 2308-2329.	7.7	7
20	Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, , .	1.5	3
21	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4045-4055.	3.2	12
22	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021, 79, 659-662.	0.9	64
23	Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. <i>Future Oncology</i> , 2021, 17, 403-409.	1.1	1
24	Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 237-246.	2.9	10
25	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	3.2	49
26	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 78-86.	3.2	154
27	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021, 7, 381-389.	1.6	28
28	Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2021, 39, 313-313.	0.8	8
29	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , 2021, 79, 334-338.	0.9	39
30	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 829-841.	13.9	961
31	A qualitative framework of non-selection factors for cytoreductive nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 3359-3365.	1.2	3
32	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 483-491.	1.9	8
33	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919.	3.2	45
34	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	13.9	956
35	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	1.5	20
36	Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16542-e16542.	0.8	0

#	ARTICLE	IF	CITATIONS
37	CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4501-4501.	0.8	30
38	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	0.9	20
39	Single-cell sequencing links multiregional immune landscapes and tissue-resident TÂcells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	7.7	179
40	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183.	0.9	2
41	Lenvatinib plus pembrolizumab in patients with either treatment-naïve or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 946-958.	5.1	100
42	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.	3.2	12
43	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956.	2.0	12
44	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 904.	1.1	10
45	Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma. <i>European Urology Open Science</i> , 2021, 31, 1-9.	0.2	2
46	Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 432-438.	2.3	19
47	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	2.6	16
48	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	3.2	25
49	Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 12-19.	0.6	39
50	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta OncolÃ³gica</i> , 2020, 59, 20-27.	0.8	3
51	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 29-39.	0.2	2
52	Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 283-293.	5.1	121
53	Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 126, 1-10.	1.3	19
54	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56.	2.6	20

#	ARTICLE	IF	CITATIONS
55	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. <i>European Urology</i> , 2020, 77, 449-453.	0.9	52
56	Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.	1.9	76
57	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
58	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020, 126, 4156-4167.	2.0	201
59	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , 2020, 5, e001079.	2.0	343
60	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255.	2.0	22
61	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020, 26, 1733-1741.	15.2	282
62	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. <i>Nature Communications</i> , 2020, 11, 4168.	5.8	46
63	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	7.7	262
64	Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 1199-1210.	1.1	4
65	Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4863-4868.	3.2	14
66	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1332-1337.	0.8	11
67	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
68	An evaluation of the role of tumor load in cytoreductive nephrectomy. <i>Canadian Urological Association Journal</i> , 2020, 14, E625-E630.	0.3	1
69	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.	0.6	12
70	Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. <i>Cancer Science</i> , 2020, 111, 907-923.	1.7	33
71	Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1154-1163.	0.8	276
72	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	3.2	20

#	ARTICLE	IF	CITATIONS
73	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82.	1.3	19
74	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640.	3.2	30
75	PTEN Expression, Not Mutation Status in <i>TSC1</i> , <i>TSC2</i> , or <i>mTOR</i> , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. <i>Clinical Cancer Research</i> , 2019, 25, 506-514.	3.2	31
76	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 1370-1385.	5.1	594
77	A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC). <i>Clinical Genitourinary Cancer</i> , 2019, 17, 356-365.e1.	0.9	11
78	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50
79	Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2019, 2, 505-514.	2.6	50
80	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 811.e9-811.e16.	0.8	6
81	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	3.2	80
82	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941.	1.1	40
83	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 268-274.e1.	0.9	29
84	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2329-2337.	0.8	17
85	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , 2019, 393, 2404-2415.	6.3	778
86	Towards individualized therapy for metastatic renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 621-633.	12.5	148
87	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e678-e688.	0.9	41
88	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115.	13.9	1,824
89	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 425-435.e4.	0.9	11
90	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)., 2019, 7, 354.		182



#	ARTICLE	IF	CITATIONS
91	The current role for adjuvant and neoadjuvant therapy in renal cell cancer. <i>Current Opinion in Urology</i> , 2019, 29, 636-642.	0.9	12
92	Comprehensive Genomic Analysis of Metastatic Nonâ€œClear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. <i>JCO Precision Oncology</i> , 2019, 3, 1-18.	1.5	7
93	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 1165-1173.	3.2	23
94	Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. <i>Cancer Discovery</i> , 2019, 9, 510-525.	7.7	169
95	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
96	Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 297-310.	5.1	207
97	Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. <i>European Urology</i> , 2019, 75, 100-110.	0.9	178
98	Combination therapy for advanced and metastatic kidney cancer. <i>Nature Reviews Urology</i> , 2019, 16, 77-78.	1.9	3
99	Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.. <i>Urology</i> , 2019, 124, 174-178.	0.5	6
100	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019, 5, 642-649.	1.6	40
101	Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 12-17.	0.8	25
102	Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 101-101.	0.8	75
103	CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4513-4513.	0.8	61
104	Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 547-547.	0.8	49
105	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 564-564.	0.8	10
106	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 581-581.	0.8	14
107	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1278-1285.	2.3	185
108	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , 2018, 114, 133-138.	0.5	12

#	ARTICLE	IF	CITATIONS
109	Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. <i>Clinical Cancer Research</i> , 2018, 24, 1554-1561.	3.2	34
110	Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3005-3013.	3.2	48
111	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	6.0	898
112	RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis. <i>BMC Cancer</i> , 2018, 18, 195.	1.1	3
113	Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 298-304.	0.9	41
114	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. <i>Urology</i> , 2018, 118, 114-118.	0.5	7
115	Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. <i>European Journal of Cancer</i> , 2018, 94, 87-94.	1.3	31
116	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	13.9	3,334
117	Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 6-12.e4.	0.9	11
118	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 986-994.	1.6	29
119	Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>European Urology</i> , 2018, 73, 62-68.	0.9	164
120	Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>Eur Urol</i> 2018;73:62-68. <i>European Urology</i> , 2018, 73, e73.	0.9	1
121	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 757-764.	0.8	43
122	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 765-772.	0.8	117
123	Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2018, 19, 1688-1698.	5.1	119
124	Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 911-912.	2.9	6
125	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 663-669.	2.9	66
126	Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. <i>Clinical Cancer Research</i> , 2018, 24, 4407-4415.	3.2	50



#	ARTICLE	IF	CITATIONS
127	Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e317-e326.	5.1	46
128	Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2018, 24, 4399-4406.	3.2	44
129	Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 91-93.	13.9	11
130	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228.	3.4	132
131	Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1176-1178.	2.9	54
132	Safety of pazopanib and sunitinib in treatment-naïve patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. <i>Journal of Hematology and Oncology</i> , 2018, 11, 69.	6.9	32
133	Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. <i>Value in Health</i> , 2018, 21, 1413-1418.	0.1	7
134	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 758-765.	1.6	89
135	The role of tivozanib in advanced renal cell carcinoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1113-1124.	1.1	14
136	Cytoreductive Nephrectomy - Patient Selection Is Key. <i>New England Journal of Medicine</i> , 2018, 379, 481-482.	13.9	88
137	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	15.2	900
138	Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4518-4518.	0.8	18
139	A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 314) Overlo	10.784314	14
140	CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4601-TPS4601.	0.8	11
141	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578.	0.8	164
142	The evolution of anti-angiogenic therapy for kidney cancer. <i>Nature Reviews Nephrology</i> , 2017, 13, 69-70.	4.1	19
143	Systemic Therapy for Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 354-366.	13.9	940
144	Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 526-533.	0.9	8

#	ARTICLE	IF	CITATIONS
145	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 962-971.	0.9	199
146	Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 639-646.	0.6	51
147	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. <i>European Urology</i> , 2017, 72, 368-376.	0.9	209
148	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 532.e7-532.e13.	0.8	25
149	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994.	0.9	39
150	Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , 2017, 103, 154-160.	0.5	12
151	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 804-834.	2.3	443
152	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 825.	3.8	366
153	Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017, 71, 405-414.	0.9	173
154	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , 2017, 197, 391-397.	0.2	10
155	Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2017, 22, 41-52.	1.9	61
156	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598.	1.6	31
157	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017, 3, 421-427.	1.6	43
158	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3916-3923.	0.8	316
159	Abstract 1771: Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory molecular analysis of tumor biomarkers. , 2017, , .		1
160	A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 431-431.	0.8	59
161	Immune Checkpoint Therapy in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 92-95.	1.0	35
162	Validation and genomic interrogation of the <sc><i>MET</i></sc> variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. <i>Cancer</i> , 2016, 122, 402-410.	2.0	18

#	ARTICLE	IF	CITATIONS
163	Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. <i>Cancer</i> , 2016, 122, 1108-1115.	2.0	34
164	Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Urology</i> , 2016, 95, 128-131.	0.5	6
165	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483.	0.8	31
166	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2016, 2, 1179.	3.4	154
167	Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2016, 114, 642-649.	2.9	43
168	Treatment of Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 888-890.	13.9	22
169	A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 175-182.	1.1	21
170	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3846-3853.	0.8	69
171	Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. <i>New England Journal of Medicine</i> , 2016, 375, 2246-2254.	13.9	640
172	Perspective: What next for treatment?. <i>Nature</i> , 2016, 537, S111-S111.	13.7	25
173	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. <i>Nature Communications</i> , 2016, 7, 13131.	5.8	140
174	Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1251-1269.	1.6	29
175	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927.	5.1	789
176	Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 994-1003.	5.1	194
177	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2016, 13, 420-431.	1.9	78
178	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 406-414.	0.9	8
179	A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2016, 21, 787-788d.	1.9	84
180	Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. <i>Lancet Oncology</i> , The, 2016, 17, e4-e5.	5.1	103

#	ARTICLE	IF	CITATIONS
181	Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 56-62.	0.9	7
182	Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours. <i>European Journal of Cancer</i> , 2016, 59, 57-64.	1.3	15
183	Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. <i>Oncology</i> , 2016, 90, 119-126.	0.9	8
184	Randomized Open-Label Phase II Trial of Apatolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1660-1668.	0.8	99
185	Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). <i>Annals of Oncology</i> , 2016, 27, 441-448.	0.6	31
186	Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2016, 43, 95-104.	0.8	9
187	Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. <i>Targeted Oncology</i> , 2016, 11, 229-234.	1.7	17
188	Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2016, 69, 345-351.	0.9	53
189	Kidney Cancer, Version 3.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 151-159.	2.3	198
190	The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1168-1170.	2.3	2
191	Testicular Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 772-799.	2.3	98
192	Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 328-337.e3.	0.9	28
193	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. <i>Lancet Oncology</i> , The, 2015, 16, 1473-1482.	5.1	762
194	Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib. <i>Oncology</i> , 2015, 89, 235-241.	0.9	9
195	Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience. <i>Journal of Urology</i> , 2015, 193, 1911-1917.	0.2	40
196	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 453-460.	0.9	5
197	Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 275-279.	0.8	7
198	Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. <i>Clinical Cancer Research</i> , 2015, 21, 1071-1077.	3.2	217

#	ARTICLE	IF	CITATIONS
199	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1814-1823.	13.9	1,004
200	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1803-1813.	13.9	4,889
201	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , 2015, 113, 1571-1580.	2.9	88
202	Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 540-547.e7.	0.9	22
203	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1430-1437.	0.8	914
204	A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. <i>European Urology</i> , 2015, 67, 100-110.	0.9	122
205	Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 59-66.	0.9	32
206	Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 193, 513-518.	0.2	20
207	Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. <i>Targeted Oncology</i> , 2015, 10, 45-53.	1.7	45
208	Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4509-4509.	0.8	14
209	CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4578-TPS4578.	0.8	24
210	Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 811-822.	2.3	9
211	Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example. <i>PLoS ONE</i> , 2014, 9, e96316.	1.1	26
212	From molecular understanding to clinical advances. <i>Nature Reviews Urology</i> , 2014, 11, 77-79.	1.9	0
213	Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and Mutations. <i>Radiology</i> , 2014, 270, 464-471.	3.6	226
214	Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2014, 120, 1871-1880.	2.0	19
215	Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial. <i>Cancer Medicine</i> , 2014, 3, 1353-1358.	1.3	8
216	Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 739-750.	1.1	69

#	ARTICLE	IF	CITATIONS
217	Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib. <i>New England Journal of Medicine</i> , 2014, 370, 1769-1770.	13.9	251
218	Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1955-1964.	3.2	208
219	Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 24-29.	0.2	15
220	Circulating proteins as potential biomarkers of sunitinib and interferon- $\gamma$ efficacy in treatment-naïve patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 151-161.	1.1	52
221	A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 181-189.	1.1	83
222	Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 760-767.	0.8	331
223	Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials. <i>European Journal of Cancer</i> , 2014, 50, 351-358.	1.3	113
224	Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. <i>European Journal of Cancer</i> , 2014, 50, 2162-2170.	1.3	82
225	Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2765-2772.	0.8	355
226	Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. <i>Journal of Urology</i> , 2014, 192, 415-419.	0.2	49
227	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296.	5.1	239
228	The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. <i>Cancer Medicine</i> , 2014, 3, 1485-1492.	1.3	110
229	Kidney Cancer, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 175-182.	2.3	56
230	Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4503-4503.	0.8	7
231	A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4525-4525.	0.8	12
232	A phase 2 multicenter study of tivatinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2013, 31, 1016-1022.	1.2	41
233	Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2013, 369, 722-731.	13.9	1,648
234	Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma. <i>Cell Reports</i> , 2013, 3, 277-281.	2.9	32



#	ARTICLE	IF	CITATIONS
235	Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 848-854.	0.9	198
236	Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 297-302.	0.9	46
237	Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 107-114.	0.9	42
238	Systemic Treatment Options for Untreated Patients With Metastatic Clear Cell Renal Cancer. <i>Seminars in Oncology</i> , 2013, 40, 436-443.	0.8	20
239	Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial. <i>European Urology</i> , 2013, 64, 994-1002.	0.9	30
240	Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 552-562.	5.1	640
241	Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3791-3799.	0.8	388
242	An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1862-1870.	3.0	231
243	Intra- and Interobserver Variability in CT Measurements in Oncology. <i>Radiology</i> , 2013, 269, 451-459.	3.6	83
244	Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2013, 108, 2470-2477.	2.9	121
245	Pazopanib versus Sunitinib in Renal Cancer. <i>New England Journal of Medicine</i> , 2013, 369, 1968-1970.	13.9	43
246	Novel Approaches Targeting the Vascular Endothelial Growth Factor Axis in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2013, 19, 299-306.	1.0	9
247	Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , 2013, 119, 2574-2581.	2.0	30
248	Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 491-504.	1.0	122
249	Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>BAP1</i> and <i>SETD2</i> : A Report by MSKCC and the KIRC TCGA Research Network. <i>Clinical Cancer Research</i> , 2013, 19, 3259-3267.	3.2	301
250	Analyzing the Pivotal Trial That Compared Sunitinib and IFN- $\alpha$ in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth. <i>Clinical Cancer Research</i> , 2012, 18, 2374-2381.	3.2	56
251	Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1371-1377.	0.8	254
252	Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 502-535.	2.3	71

#	ARTICLE	IF	CITATIONS
253	Tumor Control Outcomes After Hypofractionated and Single-Dose Stereotactic Image-Guided Intensity-Modulated Radiotherapy for Extracranial Metastases From Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1744-1748.	0.4	199
254	Improvement in Overall Survival of Patients with Advanced Renal Cell Carcinoma: Prognostic Factor Trend Analysis from an International Data Set of Clinical Trials. <i>Journal of Urology</i> , 2012, 188, 2095-2100.	0.2	35
255	Body Mass Index Is Associated With Higher Lymph Node Counts During Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2012, 79, 361-364.	0.5	16
256	Clinical Impact of Residual Extraretroperitoneal Masses in Patients With Advanced Nonseminomatous Germ Cell Testicular Cancer. <i>Urology</i> , 2012, 79, 156-159.	0.5	28
257	Outcomes in Patients With Clinical Stage III NSGCT Who Achieve Complete Clinical Response to Chemotherapy at Extraretroperitoneal Disease Site. <i>Urology</i> , 2012, 79, 1079-1084.	0.5	5
258	Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial. <i>BMC Cancer</i> , 2012, 12, 311.	1.1	30
259	Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1868-1876.	2.0	109
260	Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. <i>Cancer</i> , 2012, 118, 5078-5083.	2.0	33
261	Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>European Urology</i> , 2012, 61, 826-833.	0.9	59
262	Reply to Giuseppe Procopio, Elena Verzoni and Filippo De Braud's Letter to the Editor re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and Safety of Everolimus in Elderly Patients with Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>Eur Urol</i> 2012;61:826-33. <i>European Urology</i> , 2012, 62, e7-e8.	0.9	0
263	Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC). <i>BJU International</i> , 2012, 110, 1276-1282.	1.3	30
264	Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design. <i>Cancer</i> , 2012, 118, 981-986.	2.0	50
265	Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 335-340.	1.2	79
266	Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma: Today and Tomorrow. <i>Oncologist</i> , 2011, 16, 45-50.	1.9	79
267	Clinical Characteristics and Outcomes of Patients With Recurrence 5 Years After Nephrectomy for Localized Renal Cell Carcinoma. <i>Journal of Urology</i> , 2011, 185, 433-438.	0.2	79
268	mTOR Inhibitors in Advanced Renal Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 835-852.	0.9	112
269	A Review of Second-line Chemotherapy and Prognostic Models for Disseminated Germ Cell Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 557-576.	0.9	16
270	Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 1287-1298.	1.3	133

#	ARTICLE	IF	CITATIONS
271	Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2011, 77, 368-372.	0.5	14
272	Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumors—An Update. <i>Urology</i> , 2011, 77, 655-659.	0.5	10
273	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. <i>Lancet, The</i> , 2011, 378, 1931-1939.	6.3	1,663
274	Sarcomatoid-variant Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 454-459.	0.6	91
275	Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors: A 28-Year Experience at Memorial Sloan-Kettering Cancer Center. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1236-1241.	0.5	42
276	NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, S-1-S-29.	2.3	48
277	Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 960-977.	2.3	90
278	Sequelae of Treatment in Long-term Survivors of Testis Cancer. <i>European Urology</i> , 2011, 60, 516-526.	0.9	70
279	ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. <i>European Urology</i> , 2011, 60, 684-690.	0.9	125
280	Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. <i>Medical Oncology</i> , 2011, 28, 1527-1529.	1.2	16
281	Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Oncologist</i> , 2011, 16, 632-640.	1.9	26
282	Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 763-773.	3.0	526
283	New Perspectives on the Treatment of Metastatic Renal Cell Carcinoma: An Introduction and Historical Overview. <i>Oncologist</i> , 2011, 16, 1-3.	1.9	29
284	Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group. <i>Clinical Cancer Research</i> , 2011, 17, 5443-5450.	3.2	164
285	High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1093-1105.	1.1	16
286	Research and innovation in the development of everolimus for oncology. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 323-338.	2.5	24
287	Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 614-618.	0.6	26
288	Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 357-371.	1.1	428

#	ARTICLE	IF	CITATIONS
289	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2010, 28, 523-528.	1.2	66
290	Stage migration and increasing proportion of favorable prognosis metastatic renal cell carcinoma patients. <i>Cancer</i> , 2010, 116, 347-354.	2.0	46
291	Phase 3 trial of everolimus for metastatic renal cell carcinoma. <i>Cancer</i> , 2010, 116, 4256-4265.	2.0	1,039
292	Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , 2010, 116, 5243-5250.	2.0	25
293	Reply to L.H. Einhorn et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e740-e740.	0.8	1
294	Weighing Risks and Benefits of Postchemotherapy Retroperitoneal Lymph Node Dissection: Not So Easy. <i>Journal of Clinical Oncology</i> , 2010, 28, 519-521.	0.8	14
295	TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 1706-1713.	0.8	192
296	Genomic Deregulation during Metastasis of Renal Cell Carcinoma Implements a Myofibroblast-Like Program of Gene Expression. <i>Cancer Research</i> , 2010, 70, 9682-9692.	0.4	31
297	Reply to B.I. Rini et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e286-e287.	0.8	4
298	Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 396-403.	2.5	202
299	The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular Cancer. <i>Urology</i> , 2010, 75, 1431-1435.	0.5	47
300	Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1432-1439.	0.8	298
301	Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa. <i>Journal of Oncology Practice</i> , 2009, 5, 66-70.	2.5	32
302	Targeting Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3274-3276.	0.8	68
303	Phase I Trial of Sunitinib Malate plus Interferon- $\gamma$ for Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 28-33.	0.9	62
304	Good-risk-advanced germ cell tumors: historical perspective and current standards of care. <i>World Journal of Urology</i> , 2009, 27, 463-470.	1.2	10
305	Using the Rasch Model to Validate and Enhance the Interpretation of the Functional Assessment of Cancer Therapy "Kidney Symptom Index" Disease-Related Symptoms Scale. <i>Value in Health</i> , 2009, 12, 580-586.	0.1	7
306	Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 24-27.	0.9	148

#	ARTICLE	IF	CITATIONS
307	Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3584-3590.	0.8	2,020
308	Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 618-630.	2.3	249
309	Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 672-693.	2.3	103
310	Sunitinib and Axitinib in Renal Cell Carcinoma. , 2009, , 151-165.		0
311	Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview. , 2009, , 1-12.		0
312	Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2008, 26, 273-276.	1.2	17
313	The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. <i>Cancer</i> , 2008, 112, 800-805.	2.0	22
314	Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2008, 113, 1552-1558.	2.0	184
315	Expression of prostate-specific membrane antigen in renal cortical tumors. <i>Modern Pathology</i> , 2008, 21, 727-732.	2.9	42
316	Sunitinib therapy in renal cell carcinoma. <i>BJU International</i> , 2008, 101, 1339-1342.	1.3	18
317	Phase II Trial of Pegylated Interferon- $\alpha$ 2b in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 25-30.	0.9	20
318	Current Algorithms and Prognostic Factors in the Treatment of Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, S7-S13.	0.9	37
319	Infectious Complications from High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Germ Cell Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 595-600.	2.0	6
320	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. <i>Lancet, The</i> , 2008, 372, 449-456.	6.3	2,848
321	Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell Carcinoma. <i>Journal of Urology</i> , 2008, 180, 873-878.	0.2	131
322	Systemic Therapy for Metastatic Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2008, 35, 687-701.	0.8	39
323	Stage I Testicular Cancer Management and Necessity for Surgical Expertise. <i>Journal of Clinical Oncology</i> , 2008, 26, 2934-2936.	0.8	14
324	Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2008, 26, 5524-5529.	0.8	107

#	ARTICLE	IF	CITATIONS
325	Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. <i>Oncologist</i> , 2008, 13, 1084-1096.	1.9	198
326	Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 3763-3769.	0.8	122
327	Medical Treatment of Advanced Testicular Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 672.	3.8	307
328	Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3995-4000.	0.8	74
329	Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?. <i>Nature Reviews Urology</i> , 2008, 5, 78-79.	1.4	1
330	Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 377-382.	2.1	96
331	Signal Transduction Inhibitors in Renal Cell Carcinoma. , 2008, , 399-413.		0
332	Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 2271-2281.	13.9	3,490
333	Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 5603-5608.	0.8	92
334	Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 26, 85-90.	0.8	119
335	Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2007, 99, 974-975.	3.0	26
336	Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5597-5602.	0.8	114
337	Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>Journal of Clinical Oncology</i> , 2007, 25, 4365-4369.	0.8	132
338	Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3958-3964.	0.8	124
339	Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 247-256.	0.8	326
340	Targeted drugs for metastatic renal cell carcinoma. <i>Lancet, The</i> , 2007, 370, 2071-2073.	6.3	79
341	Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. <i>Lancet Oncology, The</i> , 2007, 8, 975-984.	5.1	428
342	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 115-124.	13.9	5,409



#	ARTICLE	IF	CITATIONS
343	Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1033-1037.	0.8	99
344	Incidence of Disease Outside Modified Retroperitoneal Lymph Node Dissection Templates in Clinical Stage I or IIA Nonseminomatous Germ Cell Testicular Cancer. <i>Journal of Urology</i> , 2007, 177, 937-943.	0.2	97
345	Immunohistochemical Expression of Hypoxia Inducible Factor-1 $\alpha$ and its Downstream Molecules in Sarcomatoid Renal Cell Carcinoma. <i>Journal of Urology</i> , 2007, 177, 1258-1263.	0.2	70
346	Sunitinib Efficacy Against Advanced Renal Cell Carcinoma. <i>Journal of Urology</i> , 2007, 178, 1883-1887.	0.2	186
347	Interferon- $\gamma$ Resistance Associated Genes in Renal Cell Carcinoma Identified by Expression Profiling. <i>Journal of Urology</i> , 2007, 177, 1264-1268.	0.2	4
348	Adjuvant Chemotherapy for Stage II Nonseminomatous Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2007, 34, 179-185.	0.8	7
349	Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. <i>Journal of Translational Medicine</i> , 2007, 5, 32.	1.8	297
350	Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer. <i>Scientific World Journal, The</i> , 2007, 7, 768-778.	0.8	43
351	Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. <i>BJU International</i> , 2007, 99, 993-997.	1.3	33
352	Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2007, 25, 487-490.	1.2	21
353	830: Clinical Outcome Following Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Men with CII Non-Seminomatous Germ Cell Tumors and a Radiographically Normal Retroperitoneum. <i>Journal of Urology</i> , 2007, 177, 277-277.	0.2	9
354	Sunitinib malate for the treatment of solid tumours: a review of current clinical data. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 553-561.	1.9	108
355	Predicting Teratoma in the Retroperitoneum in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection. <i>Journal of Urology</i> , 2006, 176, 100-104.	0.2	70
356	A brief symptom index for advanced renal cell carcinoma. <i>Health and Quality of Life Outcomes</i> , 2006, 4, 68.	1.0	10
357	Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 16-24.	0.8	1,590
358	Long-term response with sunitinib for metastatic renal cell carcinoma. <i>Urology</i> , 2006, 68, 672.e19-672.e20.	0.5	8
359	Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. <i>BJU International</i> , 2006, 97, 933-938.	1.3	71
360	Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5601-5608.	0.8	336

#	ARTICLE	IF	CITATIONS
361	A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2006, 24, 543-546.	1.2	136
362	Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2006, 107, 1793-1800.	2.0	86
363	Treatment outcome for metastatic papillary renal cell carcinoma patients. <i>Cancer</i> , 2006, 107, 2617-2621.	2.0	87
364	Medullary Renal Cell Carcinoma and Response to Therapy With Bortezomib. <i>Journal of Clinical Oncology</i> , 2006, 24, e14-e14.	0.8	47
365	Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence. <i>Journal of Clinical Oncology</i> , 2006, 24, 3101-3106.	0.8	251
366	Chemotherapy for Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2006, 24, 5493-5502.	0.8	64
367	Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2516.	3.8	1,111
368	Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 7215-7220.	3.2	159
369	Transcriptional Program Associated with IFN- $\gamma$ Response of Renal Cell Carcinoma. <i>Journal of Interferon and Cytokine Research</i> , 2006, 26, 156-170.	0.5	2
370	Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research. <i>Journal of Clinical Oncology</i> , 2006, 24, 5479-5481.	0.8	1
371	449: The Impact of Residual Extra-Retroperitoneal Masses in Patients with Advanced Non-Seminomatous Germ Cell Testicular Cancer. <i>Journal of Urology</i> , 2006, 175, 145-146.	0.2	5
372	Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 1038.	2.3	16
373	IL4 Treatment of Metastatic Renal Cell Carcinoma in 2006 : The Bridge from Yesterday to Tomorrow(IL). <i>Japanese Journal of Urology</i> , 2006, 97, 87.	0.0	0
374	Novel targets and therapies for metastatic renal cell carcinoma. <i>Oncology</i> , 2006, 20, 1745-53; discussion 1756.	0.4	9
375	Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. <i>BJU International</i> , 2005, 96, 286-290.	1.3	51
376	Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 6549-6555.	0.8	353
377	Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 6999-7004.	0.8	77
378	Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 9290-9294.	0.8	91

#	ARTICLE	IF	CITATIONS
379	Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome. <i>Journal of Clinical Oncology</i> , 2005, 23, 2781-2788.	0.8	185
380	A POSTOPERATIVE PROGNOSTIC NOMOGRAM PREDICTING RECURRENCE FOR PATIENTS WITH CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2005, 173, 48-51.	0.2	480
381	RETROPERITONEAL LYMPH NODE DISSECTION IN PATIENTS WITH LOW STAGE TESTICULAR CANCER WITH EMBRYONAL CARCINOMA PREDOMINANCE AND/OR LYMPHOVASCULAR INVASION. <i>Journal of Urology</i> , 2005, 174, 557-560.	0.2	103
382	Late relapse of testicular germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 441-445.	0.8	36
383	Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 454-463.	0.8	742
384	Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6302S-6303S.	3.2	169
385	Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 3720-3725.	0.8	176
386	Innovations and Challenges in Renal Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6277S-6281S.	3.2	38
387	Relapse-Free and Overall Survival in Patients With Pathologic Stage II Nonseminomatous Germ Cell Cancer Treated With Etoposide and Cisplatin Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 464-467.	0.8	90
388	Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors. <i>Investigational New Drugs</i> , 2004, 22, 177-179.	1.2	12
389	Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. <i>Annals of Surgical Oncology</i> , 2004, 11, 71-77.	0.7	244
390	Predicting survival of patients with metastatic renal cell carcinoma. <i>Der Urologe</i> , 2004, 43, 135-136.	2.0	5
391	Editorial: Predicting Necrosis After Chemotherapy for Advanced Nonseminomatous Germ Cell Tumor—Surrogate End Points, Decreasing Morbidity and Patient Outcome. <i>Journal of Urology</i> , 2004, 171, 1842-1843.	0.2	5
392	Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1412-21.	2.8	72
393	Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2003, 21, 341-345.	1.2	81
394	Phase II trial of anti-epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2003, 21, 99-101.	1.2	140
395	Recommendations of follow-up after treatment of germ cell tumors. <i>Seminars in Oncology</i> , 2003, 30, 382-389.	0.8	18
396	Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. <i>Cancer</i> , 2003, 98, 1611-1619.	2.0	40

#	ARTICLE	IF	CITATIONS
397	Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 33-39.	2.0	96
398	Incidence and Clinical Outcome of Patients with Teratoma in the Retroperitoneum Following Primary Retroperitoneal Lymph Node Dissection for Clinical Stages I and IIA Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2003, 170, 1159-1162.	0.2	56
399	Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groups. <i>Urologic Clinics of North America</i> , 2003, 30, 803-817.	0.8	13
400	Results of Retroperitoneal Lymph Node Dissection for Clinical Stage I and II Pure Embryonal Carcinoma of the Testis. <i>Journal of Urology</i> , 2003, 170, 1155-1158.	0.2	24
401	Long-term follow-up of bilateral sporadic renal tumors. <i>Urology</i> , 2003, 61, 921-925.	0.5	51
402	Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. <i>Urology</i> , 2003, 62, 732-736.	0.5	86
403	Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. <i>Urology</i> , 2003, 62, 1092-1096.	0.5	29
404	Renal Cell Carcinoma: A Priority Malignancy for Development and Study of Novel Therapies. <i>Journal of Clinical Oncology</i> , 2003, 21, 1193-1194.	0.8	36
405	Poor-Risk Testicular Cancer and High-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 4073-4074.	0.8	3
406	Chemotherapy for Teratoma With Malignant Transformation. <i>Journal of Clinical Oncology</i> , 2003, 21, 4285-4291.	0.8	211
407	Cluster Analysis of p53 and Ki67 Expression, Apoptosis, Alpha-Fetoprotein, and Human Chorionic Gonadotrophin Indicates a Favorable Prognostic Subgroup Within the Embryonal Carcinoma Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2003, 21, 2679-2688.	0.8	25
408	Prognostic Factors for Metastatic Kidney Cancer. <i>Cancer Treatment and Research</i> , 2003, 116, 139-153.	0.2	3
409	Phase II trial of branched peginterferon- $\alpha$ 2a (40 kDa) for patients with advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2002, 13, 1799-1805.	0.6	46
410	Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non-“Clear-Cell Histology. <i>Journal of Clinical Oncology</i> , 2002, 20, 2376-2381.	0.8	459
411	Testicular Seminoma: A Clinicopathologic and Immunohistochemical Study of 105 Cases with Special Reference to Seminomas with Atypical Features. <i>International Journal of Surgical Pathology</i> , 2002, 10, 23-32.	0.4	84
412	Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 289-296.	0.8	1,357
413	Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. <i>Urology</i> , 2002, 60, 1003-1009.	0.5	128
414	ALLELIC LOSS ON CHROMOSOMES 8 AND 9 CORRELATES WITH CLINICAL OUTCOME IN LOCALLY ADVANCED CLEAR CELL CARCINOMA OF THE KIDNEY. <i>Journal of Urology</i> , 2002, 167, 1464-1468.	0.2	53

#	ARTICLE	IF	CITATIONS
415	Salvage Chemotherapy for Patients With Advanced Pure Seminoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 297-301.	0.8	54
416	Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 302-306.	0.8	111
417	Partial nephrectomy: The rationale for expanding the indications. <i>Annals of Surgical Oncology</i> , 2002, 9, 680-687.	0.7	64
418	Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2002, 20, 327-330.	1.2	68
419	Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors. <i>Urologic Oncology</i> , 2002, 20, 239-243.	1.5	5
420	Partial nephrectomy: The rationale for expanding the indications. , 2002, 9, 680.		4
421	Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. <i>Journal of Urology</i> , 2002, 167, 1464-8.	0.2	17
422	A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2001, 166, 63-67.	0.2	677
423	Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 1312-1319.	0.8	92
424	Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse. <i>Journal of Clinical Oncology</i> , 2001, 19, 2020-2025.	0.8	95
425	Role of Postchemotherapy Adjunctive Surgery in the Management of Patients With Nonseminoma Arising From the Mediastinum. <i>Journal of Clinical Oncology</i> , 2001, 19, 682-688.	0.8	99
426	Phase II trial of irifulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2001, 19, 317-320.	1.2	23
427	Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon- $\alpha$ 2a for Patients with Advanced Renal Cell Carcinoma. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 257-263.	0.5	102
428	Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2000, 18, 265-267.	1.2	8
429	Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2413-2418.	0.8	228
430	Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 1173-1180.	0.8	187
431	Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2972-2980.	0.8	267
432	Effect of Cytokine Therapy on Survival for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 1928-1935.	0.8	187

#	ARTICLE	IF	CITATIONS
433	Calvert's Formula for Dosing Carboplatin: Overview and Concerns of Applicability in High-Dose Setting. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1434-1436.	3.0	12
434	Cytokine therapy in renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2000, 5, 249-257.	0.8	24
435	Carcinoid tumor of the kidney. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2000, 5, 108-111.	0.8	45
436	SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2000, 163, 408-417.	0.2	552
437	SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2000, , 408.	0.2	25
438	Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 615-629.	2.3	34
439	Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2530-2530.	0.8	1,641
440	A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1998, 16, 337-340.	1.2	4
441	TERATOMA WITH MALIGNANT TRANSFORMATION: DIVERSE MALIGNANT HISTOLOGIES ARISING IN MEN WITH GERM CELL TUMORS. <i>Journal of Urology</i> , 1998, 159, 133-138.	0.2	384
442	Surgery for a Post-Chemotherapy Residual Mass in Seminoma. <i>Journal of Urology</i> , 1997, 157, 860-862.	0.2	157
443	Testicular Germ-Cell Cancer. <i>New England Journal of Medicine</i> , 1997, 337, 242-254.	13.9	832
444	A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1997, 15, 353-355.	1.2	27
445	Renal cell carcinoma. <i>Current Problems in Cancer</i> , 1997, 21, 185-232.	1.0	106
446	Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 1996, 335, 865-875.	13.9	1,747
447	all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. <i>Cancer</i> , 1995, 76, 680-686.	2.0	30
448	Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. <i>Cancer</i> , 1995, 76, 824-832.	2.0	265
449	Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 1995, 13, 163-165.	1.2	28
450	Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. , 1995, 76, 824.		2



#	ARTICLE	IF	CITATIONS
451	Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1994, 12, 323-325.	1.2	26
452	Phase II trial of topotecan in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1994, 12, 143-145.	1.2	36
453	Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. <i>Cancer</i> , 1994, 73, 1892-1894.	2.0	33
454	Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. <i>Cancer</i> , 1994, 73, 2520-2526.	2.0	70
455	Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. <i>Cancer</i> , 1994, 73, 2843-2852.	2.0	33
456	Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor a randomized trial. <i>Cancer</i> , 1993, 71, 2515-2521.	2.0	51
457	Optimal treatment for advanced seminoma?. <i>Cancer</i> , 1993, 72, 3-4.	2.0	16
458	Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. <i>Cancer</i> , 1993, 72, 3313-3317.	2.0	26
459	Acute Nonlymphocytic Leukemia in Germ Cell Tumor Patients Treated With Etoposide-Containing Chemotherapy. <i>Journal of the National Cancer Institute</i> , 1993, 85, 60-62.	3.0	112
460	ROLE OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE II NONSEMINOMATOUS GERM-CELL TUMORS. <i>Urologic Clinics of North America</i> , 1993, 20, 111-116.	0.8	16
461	Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. <i>Investigational New Drugs</i> , 1992, 10, 327-330.	1.2	13
462	High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. <i>Cancer</i> , 1992, 69, 550-556.	2.0	105
463	Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. <i>Cancer</i> , 1992, 70, 2354-2357.	2.0	88
464	Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979-1989). <i>Cancer</i> , 1991, 67, 1305-1310.	2.0	127
465	Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1990, 8, 391-2.	1.2	17
466	Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. <i>Cancer</i> , 1990, 65, 2465-2470.	2.0	37
467	The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. <i>Cancer</i> , 1990, 66, 2476-2481.	2.0	119